

BRIC- National Institute of Immunology

Expression of Interest

Licensing of BRIC-NII Technologies / Patents

BRIC-NII is one of the constituent laboratory of Biotechnology Research of Innovation Council-National Institute of Immunology (BRIC-NII), Department of Biotechnology, Ministry of Science & Technology, Govt. of India, New Delhi. The Institute has a large portfolio of Innovative Technologies / IP relevant to Industry in the area of Science & Technology.

The Institute is keen to commercialize of its recent US patent, “Novel compound modulating GSK-3 activity (**Grated Patent no 11820764**)” and another Indian provisional patent “Thioxothiazolidin derivatives and uses thereof (**Filed patent application no IN202411093336**)” to interested parties.

Potential of the Technology in the Market

- The global impact of Alzheimer's disease (AD) is continuously escalating and there is an immense need to develop disease-modifying drugs. Without an effective treatment, the AD burden will grow increasingly unsustainable. Approximately >55 million people are living with dementia across the globe with nearly 10 million new cases each year. The prevalence of AD and related dementia is approximately 5.7% among those aged 65 and older. AD burden in India is very high (7.4% above 60 years) i.e. about >8 million people and is projected to double by 2030. It is estimated that by 2030 there will be 74.7 million people with dementia, and the cost of the treatment will rise to US\$ 2 trillion. Therefore, an effective molecule would be of immense importance. New disease-modifying therapy (DMT) could dramatically reduce the projected economic and societal burden of AD.
- There is an unmet need for safe and effective DMT for AD.
- Development of SG001 as safe DMT will have better patient compliance.

The Salient features of the patented process is given below

The patent related to the development of Novel method of small molecule mediated regulation of total GSK3 activity and methods of use for treating or preventing GSK3 kinase-mediated disorders, such as neurological diseases: neurodegenerative diseases e.g. Alzheimer's disease,

- Alzheimer's disease (AD) stands out as the only major disease without any form of preventative of disease modifying drug available.
- Exploration for the first disease-modifying therapeutic strategy for AD is one of the greatest challenges in the AD drug development.
- In AD, an abnormal increase in GSK-3 levels and activity has been associated with neuronal death, NFT, plaque formation, and neurite retraction, as well as a decline in cognitive performance. GSK-3 is a prominent drug target.
- However, so far developed preclinical and clinical GSK3 inhibitors have shown sub-optimal potency, poor GSK-3 selectivity over other CNS targets and closely related kinases, and chronic toxicity. Hence, other ways of modulating GSK3 such as to downregulate GSK3 would be a healthier approach.
- SG001 down-regulates Total GSK3 and activated autophagy
- SG001 a potential disease-modifying therapy capable of ameliorating both Ab42 and tau pathology.

Expression of interest from Indian and Multi-nationals are invited for securing the license to manufacture and market the products in any countries of interest

The interested companies may furnish the Technical (Annexure I) bids in sealed covers. Only the parties who have proven expertise as evidenced in the technical bid will be considered for the first level of interaction. Costing for the Process will be decided after mutual discussion with competent parties as per NII guidelines.

Quotes superscribed as “**Technical Bid for patent licensing**” should be sent in an envelope to The Director, National Institute of Immunology New Delhi -110067 with a covering letter addressed to The Director, National Institute of Immunology New Delhi -110067 Last date for the submission of bid is by **02.04.2025**.

The sealed covers containing technical bid will be opened at Director Office, NII in the presence of representatives of bidders. The date will be intimated in advance.

Director, BRIC-NII, reserves the right to revise, reject, re-seek the EoI, if necessary. The decision of the Director, BRIC-NII will be final.

Technical Bid Details
(Company Letter Head)

1	Name of the Firm Address Contact details (Mobile and Email) Website :	
2	Details of Incorporation, Operational details including branches/subsidiaries	
3	Expertise of the Company	
4	Details of Manufacturing / Marketing details (GST, PAN, TAN and others) Legal document copy may be furnished	
5	Details of the Patent for which license is sought	
6	The Mode of licensing sought	Non Exclusive Exclusive
7	Any other details, deemed important about the Company	
8	Details of Authorised person making the offer (including designation, Mobile, email etc.)	
9	Signature with seal	